规格 | 价格 | 会员价 | 库存 | 数量 | |||
---|---|---|---|---|---|---|---|
{[ item.pr_size ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]} |
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
描述 | Thromboxane A2 (TXA2), a potent mediator of platelet aggregation and inducing constriction of various types of smooth muscle (SM) including vascular, renal and pulmonary SM, mediates its actions in humans by binding to the TPα and TPβ isoforms of the thromboxane prostanoid receptor (TP). NTP42 is a novel antagonist of the TP, currently in development for the treatment of pulmonary arterial hypertension (PAH) by antagonizing the action of TXA2. In an MCT-induced PAH rat model, NTP42 (0.25 mg/kg BID, p.o.) reduced the MCT-induced PAH, including mean pulmonary arterial pressure (mPAP) and right systolic ventricular pressure (RSVP), being at least comparable to the standard-of-care drugs Sildenafil (50 mg/kg BID, p.o.) or Selexipag (1 mg/kg BID, p.o.) in bringing about these effects. Moreover, NTP42 was superior to Sildenafil and Selexipag in significantly reducing pulmonary vascular remodelling, inflammatory mast cell infiltration and fibrosis in MCT-treated animals[1]. |
计算器 | ||||
存储液制备 | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.70mL 1.94mL 0.97mL |
19.40mL 3.88mL 1.94mL |
CAS号 | 2055599-51-2 |
分子式 | C25H23F2N3O5S |
分子量 | 515.53 |
SMILES Code | O=S(C1=CC(C#N)=CC=C1OC2=CC(C3=CC=C(OC(F)F)C=C3)=CC=C2)(NC(NC(C)(C)C)=O)=O |
MDL No. | MFCD32669796 |
别名 | |
运输 | 蓝冰 |
InChI Key | RIIKDGPBTPECSW-UHFFFAOYSA-N |
Pubchem ID | 124147085 |
存储条件 |
In solvent -20°C:3-6个月-80°C:12个月 Pure form Sealed in dry, 2-8°C |
溶解方案 |
请根据您的动物给药指南选择适当的溶解方案。 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|